Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Megan E Cavet, Paul J Gomes, Warner W Carr & Jon I Williams. (2018) Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis. Journal of Asthma and Allergy 11, pages 29-39.
Read now
Read now
Paramdeep S Bilkhu, Shehzad A Naroo & James S Wolffsohn. (2015) Treatment of ocular allergies: nonpharmacologic, pharmacologic and immunotherapy. Expert Review of Ophthalmology 10:3, pages 257-266.
Read now
Read now
Duck Soo Lim, Yoo Seok Youn, Seung Jun Kwack, Hyo Min Kwak, Seong Kwang Lim, Ji Yun Kim, Yoon Mi Um, Jung Dae Lee, Ji Hyeon Hyeon, Yeon Joo Kim, Hyung Sik Kim & Byung-Mu Lee. (2014) Comparative Efficacy and Bioequivalence of Novel H1-Antihistamine Bepotastine Salts (Nicotinate and Salicylate). Journal of Toxicology and Environmental Health, Part A 77:22-24, pages 1451-1466.
Read now
Read now
Leonard Bielory, Shubhasree Duttachoudhury & Andrea McMunn. (2013)
Bepotastine besilate for the treatment of pruritus. Expert Opinion on Pharmacotherapy 14:18, pages 2553-2569.
Read now
Read now
Articles from other publishers (11)
Bisant A. Labib & DeGaulle I. Chigbu. (2022) Therapeutic Targets in Allergic Conjunctivitis. Pharmaceuticals 15:5, pages 547.
Crossref
Crossref
Shruti Ayyappanavar, Sriya Sridhar, Kiran Kumar, CR Jayanthi, SureshBabu Gangasagara, BL Sujatha Rathod, B Preethi & Preeti Mittal. (2021) Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis. Indian Journal of Ophthalmology 69:2, pages 257.
Crossref
Crossref
Pascale Dupuis, C. Lisa Prokopich, Alexander Hynes & Harold Kim. (2020) A contemporary look at allergic conjunctivitis. Allergy, Asthma & Clinical Immunology 16:1.
Crossref
Crossref
Pushpendra ChotiyaDrDrArvind ChauhanDrDr. (2020) AN EFFICACY COMPARISON STUDY BETWEEN TOPICAL ANTI ALLERGIC DRUGS IN PATIENTS WITH ALLERGIC CONJUNCTIVITIS IN WESTERN RAJASTHAN. PARIPEX INDIAN JOURNAL OF RESEARCH, pages 22-24.
Crossref
Crossref
Vadlakonda Sruthi, ResuNeha Reddy, K Sowmini & NagurSharone Grace. (2020) To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital. Indian Journal of Pharmacology 52:6, pages 476.
Crossref
Crossref
Shiyan Cao, Shining Cao, Aiwei Chen, Lanlan Yang & Yuan Chen. (2019) Comparing Efficacy and Safety of Olopatadine and Emedastine in
Patients with Allergic Conjunctivitis. International Journal of Pharmacology 15:3, pages 327-335.
Crossref
Crossref
Leonard Bielory & Dovid Schoenberg. (2019) Emerging Therapeutics for Ocular Surface Disease. Current Allergy and Asthma Reports 19:3.
Crossref
Crossref
Lakshey Dudeja, Anuja Janakiraman, Ishani Dudeja, Kaustubh Sane & Manohar Babu. (2019) Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis. Indian Journal of Ophthalmology 67:9, pages 1400.
Crossref
Crossref
Mayret Castillo, Neil W Scott, Mohammad Z Mustafa, Mohammed S Mustafa & Augusto Azuara-Blanco. (2015) Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Kyoung-Ah Kim & Ji-Young Park. (2013) Pharmacokinetic Comparisons of Bepotastine Besilate and Bepotastine Salicylate in Healthy Subjects. Clinical Drug Investigation 33:12, pages 913-919.
Crossref
Crossref
Terrence P. O’Brien. (2013) Allergic conjunctivitis. Current Opinion in Allergy & Clinical Immunology 13:5, pages 543-549.
Crossref
Crossref